Results 341 to 350 of about 93,898 (384)
Some of the next articles are maybe not open access.
Eosinophils in the pathogenesis of paediatric severe asthma
Current Opinion in Allergy & Clinical Immunology, 2014The importance and functional contribution of eosinophils to the pathogenesis of severe asthma was questioned when adult studies reported neutrophilic inflammation and Th17 cells were central to disease.Eosinophilic inflammation, atopic sensitization and airway remodelling are the hallmark features of severe asthma in children.
Sejal, Saglani, Clare M, Lloyd
openaire +2 more sources
Mepolizumab for the treatment of severe eosinophilic asthma
American Journal of Health-System Pharmacy, 2017Published data on the pharmacology, pharmacokinetics and pharmacodynamics, and clinical efficacy and safety of the interleukin-5 antagonist mepolizumab are reviewed.Asthma of the eosinophilic phenotype is characterized by persistent eosinophilic airway inflammation promoted primarily by T-helper type 2 cytokines, the key regulator of eosinophils ...
Mara N, Poulakos +3 more
openaire +2 more sources
PERIPHERAL BLOOD EOSINOPHIL SHIFTS IN SEVERE, UNCONTROLLED ASTHMA
Annals of Allergy, Asthma & Immunology, 2018Introduction Greater clarity is needed on peripheral blood eosinophil counts (BEC) associated with events such as exacerbations or responsiveness to biologics in severe asthma. Inclusion criteria and prespecified analyses on peripheral BECs vary between clinical trials. Stability of BEC on repeated measures in this population is unknown.
F Trudo +5 more
openaire +1 more source
Mepolizumab in the Treatment of Severe Eosinophilic Asthma
Immunotherapy, 2015IL-5 is crucial in the pathogenesis and evolution of eosinophilic asthma. Mepolizumab is a high-affinity humanized monoclonal antibody of the IgG1/k subtype that inhibits the binding of IL-5 to its receptor expressed on eosinophils, thereby inducing significant reduction in eosinophil circulation, as well as asthma exacerbations and corticosteroid ...
FAINARDI, Valentina +2 more
openaire +3 more sources
Biological treatment is approved for severe eosinophilic asthma
BMJ, 2016Draft guidance from the National Institute for Health and Care Excellence (NICE) recommends the monoclonal antibody mepolizumab as an option to treat adult patients with severe refractory asthma and raised eosinophil levels.1 The decision follows an agreement by the manufacturer, GlaxoSmithKline (GSK), to reduce the price of the drug—which has a list ...
openaire +2 more sources
Eosinophilic and noneosinophilic asthma: Beyond severe asthma
2023Tara F. Carr, Sanjay B. Patel
openaire +1 more source
Primary lysis of eosinophils in severe desquamative asthma
Clinical & Experimental Allergy, 2014SummaryPrimary lysis of eosinophils liberates free eosinophil granules (FEGs) releasing toxic proteins in association with bronchial epithelial injury repair. Eosinophil lysis may be significantly pathogenic. Bronchial mucosal FEGs are associated with uncontrolled asthma, severe asthma, aspirin‐sensitive asthma, and lethal asthma. FEGs in the bronchial
openaire +2 more sources
Emerging Therapies in Severe Eosinophilic Asthma
Archivos de Bronconeumología (English Edition), 2017Pee Hwee, Pang +1 more
openaire +2 more sources
The prevalence of severe asthma and severe eosinophilic asthma in Finland
Epidemiology, 2023Arja Viinanen +6 more
openaire +1 more source